Interleukin (IL)-17 inhibitors treat psoriasis by reducing inflammation.
What IL-17 Inhibitors Treat
Healthy amounts of pro-inflammatory cytokines protect and heal tissue inflammation.
However, these biologic medications are not without risks.
ipopba / Getty Images
Most notably, IL-17 inhibitors areimmunosuppressants.
Summary
IL-17 inhibitors block the inflammatory pathway of interleukin-17A.
These biologic medications are an extremely effective FDA-approved treatment option for people with psoriasis and psoriatic arthritis.
These monoclonal antibodies are a game-changer.
These biologic drugs are all FDA-approved for the treatment of psoriasis and psoriatic arthritis.
Cosentyx and Taltz are also used to treat a form of inflammatory arthritis called ankylosing spondylitis.
Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic autoimmune disorders.
IL-17 inhibitors target IL-17A’s inflammatory pathways and are used to treat psoriatic disease.
IL-17 inhibitors are immunosuppressive therapies that suppress the immune system’s ability to make excessive pro-inflammatory cytokines.
2021;Volume 10:409-418. doi:10.2147/ITT.S240891
Lonnberg, Skov L, Zachariae C.Targeting of interleukin-17 in the treatment of psoriasis.CCID.
2012;167(4):717-724. doi:10.1111/j.1365-2133.2012.11099.x
Iwakura Y.The IL-23/IL-17 axis in inflammation.Journal of Clinical Investigation.
A new era in treatment of psoriasis and other skin diseases.pdia.
2018;4(2):e000656.
doi:10.1136/rmdopen-2018-000656
Dermatology Times.Psoriasis Updates: Comparing IL-23 and IL-17 Inhibitors, TNF Blockers.
2019;78(9):1167-1178. doi:10.1136/annrheumdis-2019-215356
NIH: National Cancer Institute.Immunosuppression.
2019;23(1):50-74. doi:10.1177/1203475418811335
